Production (Stage)
BioLife Solutions, Inc.
BLFS
$21.78
-$0.32-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 29.88% | 44.21% | 29.69% | -3.11% | -36.83% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 29.88% | 44.21% | 29.69% | -3.11% | -36.83% |
| Cost of Revenue | 31.70% | 22.38% | 23.30% | -26.23% | -59.26% |
| Gross Profit | 28.96% | -7.38% | 35.85% | 35.10% | -12.46% |
| SG&A Expenses | 10.37% | 2.17% | -5.07% | -17.13% | -25.91% |
| Depreciation & Amortization | 2.03% | 100.49% | -30.64% | -35.28% | -51.45% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.79% | 44.76% | -0.58% | -23.69% | -41.42% |
| Operating Income | 63.03% | -46.07% | 82.17% | 75.79% | 58.35% |
| Income Before Tax | 86.36% | -86.42% | 88.97% | -29.55% | 63.12% |
| Income Tax Expenses | -17.65% | 43.78% | -124.35% | -- | -81.52% |
| Earnings from Continuing Operations | 86.00% | -85.56% | 89.22% | -29.50% | 63.32% |
| Earnings from Discontinued Operations | -- | 140.62% | -- | -189.96% | -40.64% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 95.62% | 183.30% | 94.15% | -103.15% | 25.47% |
| EBIT | 63.03% | -46.07% | 82.17% | 75.79% | 58.35% |
| EBITDA | 116.32% | -44.30% | 113.61% | 94.90% | 78.51% |
| EPS Basic | 95.78% | 180.04% | 94.48% | -91.82% | 29.40% |
| Normalized Basic EPS | 86.76% | -43.75% | 81.79% | 74.91% | 61.88% |
| EPS Diluted | 95.78% | 176.93% | 94.48% | -91.82% | 29.40% |
| Normalized Diluted EPS | 86.76% | -45.38% | 81.79% | 74.91% | 61.88% |
| Average Basic Shares Outstanding | 3.75% | 4.07% | 5.98% | 5.90% | 5.58% |
| Average Diluted Shares Outstanding | 3.75% | 7.16% | 5.98% | 5.90% | 5.58% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |